Le PU medical spending return to the proper path to enter the field of cardiovascular medicine

Not long ago, because of the use of super raise funds to buy a house to buy a car and was criticized by the outside of Le Pu Medical (300003, closing price of 25.61 yuan) finally began to spend money on the straight path. The company decided to enter the cardiovascular drug market, the partner is another a-share pharmaceutical company, the side of the pharmaceutical industry (600253, closing price of 7.52 yuan).　　And before the extravagant spending methods, le PU medical investment appears to be more cautious, the initial investment accounted for only 49% of the project, and set up a suspected agreement on the terms of the game, in order to achieve a certain conditions before the proportion of the shareholding to 51%. In February this year, Le Pu Medical decided to use 179 million yuan super raise funds to invest in domestic and foreign marketing network projects, accounting for the proportion of total over 30%. But the company then will be 73.3 million yuan to buy a house to buy a car, this money accounted for 179 million yuan of 41.04%, and accounted for over $623 million of the capital of 11.77%.　　The move was criticized by many investors as a "spending spree". Le PU Medical Service announced today (June 30) that the company has been with the daily medicine and Henan Fang Chinese Herbal Medicine Co., Ltd. (hereinafter called the Chinese Herbal Medicine) jointly signed the "Investment cooperation Framework Agreement", the company will be the next to the pharmaceutical industry to take stock options, by the Le General medical medicine on the other hand of the next Chinese medicine to increase capital,　　The Chinese herbal medicine as the two sides to develop cardio-cerebrovascular drugs business professional platform. Data show that the Chinese herbal medicine is a drug production and sales of qualified enterprise, the company registered capital of 47.69 million yuan, the company has formed a scale of production and through the national GMP certification.　　At present, the drug industry directly and indirectly hold the date of 100% stake in Chinese medicine. According to the announcement, after the framework agreement signed, the medicine industry should be entrusted with the "Atorvastatin Calcium capsules" market development and terminal development business.　　From the days of the annual report of the pharmaceutical industry can be seen, the drug last year after the listing, in only 4 months to achieve a profit of 10 million yuan. Such a piece of "cake" on the other, why should the pharmaceutical industry to woo Pu medicine to "divide food"?　　In this respect, Xiang Wealth Securities analyst Ye Shi to the daily economic news, said one is because the side of the drug industry's main direction for the raw materials, and the preparation is its short plate; Secondly, le Pu medical although main medical equipment, but in the cardiovascular department this aspect of the marketing network has a certain advantage, to help product open sales. However, this investment is not a step in place.　　The announcement said that the investment will be divided into two steps, the first step, le Pu medical through the increase in the way the Chinese herbal medicine 49% of the day, the day of medicine holding the day of Chinese medicine 51% stake; the second step, in meeting the relevant conditions, the implementation of further restructuring, Le PU Medical will hold the day of 51% stake in Chinese Medicine, the day of the drug From 49% Equity to 51% of the change in ownership, Le PU Medical has set up a suspected gambling agreement here.　　Ye Shi that this reflects the firm's cautious state of investing in the investment. "49% of the investment is not counted into the main business report items, only to be counted into the investment income, and more than 50% of the proportion of the project will be merged into the main business。 This is to protect against risk, it is obvious that the company's attitude on this investment is very cautious. "Ye Shi said.